GlyphAgo

The first patient has been dosed in a Phase 2a clinical trial of GlyphAgo, an investigational treatment for generalized anxiety disorder and sleep disturbance. The announcement marks the start of patient enrollment in the mid-stage study, a key step in testing whether the drug can safely and effectively address both anxiety and related sleep problems.